Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?
NCT ID: NCT02044445
Last Updated: 2014-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
154 participants
INTERVENTIONAL
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The time interval between hCG administration and oocyte retrieval is of critical importance since the time after luteinizing stimulus is a period of intense processes including the start of luteinization, expansion of cumulus cells and oocyte meiotic maturation.
The commonly practiced hCG administration time of 33 to 36 h in most IVF cycles aims to avoiding spontaneous ovulation before oocyte retrieval. However, several studies have shown that significantly more high quality embryos have been obtained with a prolonged hCG-to-oocyte interval of 38 h. It has been hypothesized that longer interval would be beneficial in improving oocyte quality and achieving optimal maturation.
Currently there are no data on the effect of the time interval between hCG administration and oocyte retrieval on IVF outcome in GnRH antagonist cycles. The aim of this study is to determine whether there is any difference in in vitro fertilization outcome when oocyte retrieval takes place at 36 h or 38 h following hCG administration
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dual Triggering in Patients With a High Immature Oocyte Rate
NCT02813239
Double Trigger in Patients With Low Number of Oocytes Retrieved Per Number of Preovulatory Follicles
NCT04407065
Follicle Size and Oocyte Development
NCT03660813
Early Luteal Hormones and IVF Outcomes After hCG Triggering
NCT04693624
IVF Treatment in Women With Immature Oocytes in Previous Cycle
NCT02368964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
36 h group
Oocyte retrieval will be performed 36 hours after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
38 h group
Oocyte retrieval will be performed 38 hours after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* regular spontaneous menstrual cycle (24-35 days)
* age ≤ 43 years
* FSH ≤ 20 IU/L
Exclusion Criteria
* Women with Stage III-IV Endometriosis
* Women undergoing natural cycle IVF
20 Years
43 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
E.M. Kolibianakis
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHR-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.